Downloads

  1. Successful EU MAA Submission Enabled By U.S.–EU Regulatory Collaboration 5/27/2026

    Facing EU MAA complexity? Learn how one oncology sponsor met a fixed EMA deadline through global regulatory coordination, rapid dossier adaptation, and real-time submission execution.

  2. Relieving Pressure During Preparation Of A High-Volume sNDA 5/27/2026

    Managing a complex sNDA under pressure? See how one sponsor achieved an early FDA submission through coordinated publishing, regulatory strategy, and flawless execution.

  3. Supporting Global Approval Of A First-In-Class Gene Therapy For A Rare Genetic Disorder 5/27/2026

    Global approvals for a first-in-class gene therapy don’t happen by chance. See how adaptive oversight and inspection readiness kept a complex rare disease program moving forward.

  4. Clinical Trial Ads, Informed Consent, And Half-Hearted Regulation 5/27/2026

    Should informed consent really start with clinical trials ads? And if not, why do IRBs need to be involved in their approval? Paul Ivisin unravels the tangled web of IRBs, regulators, and clinical trial advertisements.

  5. RTSM Rescue Studies Are On The Rise 5/26/2026

    As RTSM technology continues to evolve, clinical trial rescues are becoming increasingly common. Explore the rise of the rescue trend and why more sponsors are ready to change course.

  6. How Expert Medical Information Support Strengthened A Rare Respiratory Therapy Launch 5/26/2026

    Embedded medical information expertise enabled compliant, real‑time scientific engagement with healthcare professionals at a high‑profile congress during a critical product launch.

  7. Urgent Compliance Recovery Following Vendor Transition 5/26/2026

    Rapid local leadership, clear ownership of corrective actions, and governed oversight enabled time‑critical remediation of legacy safety gaps, restoring regulatory confidence and protecting market continuity under intense inspection pressure.

  8. Inspection Facilitation Without Local MAH Presence 5/26/2026

    Local expertise and centralized oversight ensured compliant, well‑coordinated inspections across countries, reducing operational risk and client burden while maintaining consistent authority engagement.

  9. Continuity And Risk Mitigation Following Unexpected QPPV Resignation 5/26/2026

    Rapid escalation and clear interim governance ensured compliance and operational continuity following an unexpected QPPV resignation, reducing inspection risk during a critical pharmacovigilance transition.

  10. Transforming European Case Intake Operations 5/26/2026

    Centralized intake and semi‑automation brought clarity and control to European safety reporting, improving oversight, data quality, and compliance across multiple partners and countries.